These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 14680796)

  • 1. [Comparison of changes in biochemical markers of bone remodeling after 6 months of hormone replacement therapy with either transdermal 17 beta-estradiol or equine conjugated estrogen plus nomegestrol acetate. Gynécol Obstét Fertil 2003; 31 : 434-441].
    Ribot C
    Gynecol Obstet Fertil; 2003 Dec; 31(12):1079-80. PubMed ID: 14680796
    [No Abstract]   [Full Text] [Related]  

  • 2. [Comparison of changes in biochemical markers of bone turnover after 6 months of hormone replacement therapy with either transdermal 17 beta-estradiol or equine conjugated estrogen plus nomegestrol acetate].
    Collette J; Viethel P; Dethor M; Chevallier T; Micheletti MC; Foidart JM; Reginster JY
    Gynecol Obstet Fertil; 2003 May; 31(5):434-41. PubMed ID: 14567121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of estrogen on bone-turnover and its prevention and control of osteoporosis ].
    Lin SQ
    Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(11):728-9. PubMed ID: 15949374
    [No Abstract]   [Full Text] [Related]  

  • 4. Markers of bone turnover in postmenopausal women receiving hormone replacement therapy.
    Hamwi A; Ganem AH; Grebe C; Kerschan-Schindl K; Preisinger E; Boschitsch E; Bieglmayer C
    Clin Chem Lab Med; 2001 May; 39(5):414-7. PubMed ID: 11434391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of transdermal 17 beta-estradiol and oral conjugated equine estrogens on biochemical parameters of bone resorption in natural menopause.
    Reginster JY; Christiansen C; Dequinze B; Deroisy R; Gaspard U; Taquet AN; Franchimont P
    Calcif Tissue Int; 1993 Jul; 53(1):13-6. PubMed ID: 8394191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Basic principles of hormone replacement therapy in the postmenopause].
    Dören M
    Ther Umsch; 2000 Oct; 57(10):628-34. PubMed ID: 11081374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdermal estrogen therapy improves lipid profile and osteoporosis in postmenopausal liver transplant patients.
    Isoniemi H; Appelberg J; Nilsson C; Mäkelä P; Risteli J; Höckerstedt K
    Transplant Proc; 2001; 33(1-2):1472-3. PubMed ID: 11267379
    [No Abstract]   [Full Text] [Related]  

  • 8. Hormone replacement therapy in the prevention and treatment of osteoporosis.
    Delmas PD
    Osteoporos Int; 1997; 7 Suppl 1():S3-7. PubMed ID: 9205638
    [No Abstract]   [Full Text] [Related]  

  • 9. [Prevention of postmenopausal osteoporosis: how effective is transdermal hormone substitution? (Continuous estradiol plus sequential oral norethisterone acetate)].
    Gass R; Neff M
    Schweiz Med Wochenschr; 1995 Aug; 125(34):1583-91. PubMed ID: 7569830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.
    Bhattoa HP; Bettembuk P; Balogh A; Szegedi G; Kiss E
    Osteoporos Int; 2004 May; 15(5):396-404. PubMed ID: 14676992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biochemical markers of bone turnover. New aspect. Effects of androgen and estrogen on biochemical markers of bone turnover].
    Ohnaka K; Takayanagi R
    Clin Calcium; 2009 Aug; 19(8):1118-24. PubMed ID: 19638695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis.
    Gonnelli S; Cepollaro C; Pondrelli C; Martini S; Monaco R; Gennari C
    J Bone Miner Res; 1997 Apr; 12(4):624-31. PubMed ID: 9101374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen therapy in postmenopausal osteoporosis. What we know and what we don't.
    Roux C
    Rev Rhum Engl Ed; 1997 Jun; 64(6):402-9. PubMed ID: 9513613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nomegestrol acetate may enhance the skeletal effects of estradiol on biochemical markers of bone turnover in menopausal women after a 12-week treatment period.
    Nguyên-Pascal ML; Thomas JL; Bergougnoux L; Garnero P; Drapier-Faure E; Delmas PD
    Climacteric; 2005 Jun; 8(2):136-45. PubMed ID: 16096169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy.
    Hassager C; Jensen LT; Pødenphant J; Thomsen K; Christiansen C
    Calcif Tissue Int; 1994 Jan; 54(1):30-3. PubMed ID: 8118750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoring aging bones.
    Rosen CJ
    Sci Am; 2003 Mar; 288(3):70-7. PubMed ID: 12616861
    [No Abstract]   [Full Text] [Related]  

  • 17. The smallest available estradiol transdermal patch: a new treatment option for the prevention of postmenopausal osteoporosis.
    Bertonazzi A; Nelson B; Salvador J; Umland E
    Womens Health (Lond); 2015 Nov; 11(6):815-24. PubMed ID: 26618621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?
    Langdahl BL; Loft AG; Møller N; Weeke J; Eriksen EF; Mosekilde L; Charles P
    J Bone Miner Res; 1997 Jan; 12(1):78-88. PubMed ID: 9240729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Biochemical bone markers and biological effects of osteoporosis therapy].
    Kovacev-Zavisić B; Novaković-Paro J; Curić N; Icin T; Todorović-Djilas L; Kovacev N
    Vojnosanit Pregl; 2012 May; 69(5):432-6. PubMed ID: 22764547
    [No Abstract]   [Full Text] [Related]  

  • 20. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding.
    Marslew U; Overgaard K; Riis BJ; Christiansen C
    Obstet Gynecol; 1992 Feb; 79(2):202-10. PubMed ID: 1309944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.